Chemical Synthesis Peptide Drugs Market Set To Reach USD 4.82 Billion By 2034, Growing At A 6.54% CAGR Driven By Automation And Green Chemistry Advances

What are the Key Trends in the Chemical Synthesis Peptide Drugs Market?

• In November 2025, Biogen Inc. and Dayra Therapeutics entered into a research collaboration to discover and evolve oral macrocyclic peptides for priority targets in immunological concerns.
• In October 2025, SK pharmteco, a global contract development and manufacturing organization (CDMO), invested $6.1 million in its Rancho Cordova facility to boost and equip a new lab and CGMP-Kilo-scale facility for Solid-Phase Peptide Synthesis (SPPS) and purification.

What is the Significant Limitation in the Market?

The global market is facing challenges in the higher spending of starting materials, complex multi-step processes, high solvent waste (Process Mass Intensity), and struggles in the synthesis of longer peptides (error accumulation, purification).

Executive Summary Table

For instance,

• In August 2025, Amphastar Pharmaceuticals signed an exclusive licence agreement with Nanjing Anji Biotechnology to raise the evolution, production, use and commercialisation of three peptides in the US and Canada.
  

How did the Asia Pacific Grow Notably in the Market in 2024?

During 2025-2034, the Asia Pacific is anticipated to expand at a significant CAGR in the chemical synthesis peptide drugs market. Specifically, China and India are facilitating affordability for peptide synthesis, with growth in geriatric populations and lifestyle changes rising demand for peptide drugs for diabetes, cancer, and metabolic disorders. Currently, Chinese researchers are working on bifunctional peptides targeting integrins (HM-3 and AP25) to accelerate anti-angiogenic and anti-proliferative effects against gastric cancer cells.

Few Examples of FDA-Approved Peptide Drugs in 2025

Segmental Insights

By synthesis method analysis

How did the Chemical Synthesis Segment Lead the Market in 2024?

In 2024, the chemical synthesis segment captured the biggest share of the chemical synthesis peptide drugs market. The widespread manufacturers are highly using solid-phase peptide synthesis (SPPS) and, for longer sequences, Native Chemical Ligation (NCL). The era is leveraging nanoparticles and liposomes to protect them from degradation and accelerate targeting to particular tissues.

The non-chemical synthesis segment is anticipated to register rapid expansion. This mainly comprises biological synthesis (recombinant DNA technology and fermentation) and chemoenzymatic peptide synthesis (CEPS). Whereas diverse solutions, including phage, yeast, or mRNA display, are employed for high-throughput screening of large peptide libraries to find new drug candidates. A major contribution is N-to C-direction synthesis and the use of "green" reaction media (such as frozen aqueous solutions or supercritical carbon dioxide) in enzymatic reactions.

By synthesis technology analysis

Why did the Solid-Phase Peptide Synthesis (SPPS) Segment Dominate the Market in 2024?

The solid-phase peptide synthesis (SPPS) segment held the largest share of the chemical synthesis peptide drugs market. Mainly, this technology is automation-friendly, versatile (non-natural AAs, modifications), scalable, and highly effective for complex sequences. The globe is putting efforts into the adoption of Sustainable Ultrasound-Assisted SPPS (SUS-SPPS), which critically lowers solvent usage (by 83–88%), reaction times, and washing steps by integrating multiple operations into a single step.

However, the hybrid phase peptide synthesis segment is predicted to expand fastest. The technology is merging SPPS (easy purification) with LPPS (scalability), to boost yield, purity, & cost-effectiveness for large-scale therapeutic peptides. Recently, Cambrex's API facility expanded in Waltham, Massachusetts, and CordenPharma's new peptide facility construction near Basel, Switzerland, to leverage peptide drug candidates, such as Viking Therapeutics' VK2735.

By product type analysis

Which Product Type Led the Chemical Synthesis Peptide Drugs Market in 2024?

The reagents & consumables segment led with a dominant share of the market in 2024. The segment primarily comprises different resins, amino acids, solvents, and coupling agents to escalate effectiveness, sustainability, and scalability. Research activities in 2024 explored Oxyma-based reagents, such as COMU and PyOxim are preferred to raise efficiency and better solubility, as an option for HOBt/HOAt-based reagents.

On the other hand, the services segment is estimated to expand rapidly. Companies are facilitating custom synthesis, large-scale GMP-compliant production, and analytical testing. Also, they are promoting peptide modifications, including cyclization, PEGylation, lipidation, and the addition of fluorescent labels or D-amino acids. For the entire analysis, the market is implementing the use of mass spectrometry

By end-user analysis

Why did the Pharmaceutical & Biotechnology Companies Segment Lead the Market in 2024?

The pharmaceutical & biotechnology companies segment captured a dominant share of the chemical synthesis peptide drugs market in 2024. These firms are stepping towards innovations in AI design, green chemistry (like solvent reduction), automation (BioDuro), and advanced delivery (Merck/Cyprumed). Furthermore, Novartis/PeptiDream are involved in the development of macrocyclic peptide discovery for radioligands.

However, the CDMOs/CROs segment is estimated to witness rapid expansion during 2025-2034. They are fostering their contribution in major capacity progressions, strategic alliances, and technological breakthroughs, to fulfil the raised demand for GLP-1 receptor agonists targeted therapies

By application analysis

Which Application Dominated the Chemical Synthesis Peptide Drugs Market in 2024?

The therapeutics segment held the largest revenue share of the market in 2024. The globe is pushing the development of tumor-homing peptides, cell-penetrating peptides (CPPs), and innovative delivery systems (nanoparticles) for targeted cancer therapy. Many latest studies are demonstrating modular assembly, such as "LEGO-like" construction by integrating functional modules, including targeting, cell penetration for multifunctional drugs.

Furthermore, the diagnostics segment will witness the fastest expansion. The emergence of the latest peptide-based imaging agents, including $^{18}$F-PSMA-1007, is used for non-invasive and precise prostate cancer detection via PET scans. Also, includes $^{177}$Lu-FAP-2286, a theranostic agent in development and assisting in integrating an imaging function with targeted radiotherapy for solid tumors

The Market Value Chain Analysis

R&D

The chemical synthesis peptide drugs market is exploring the discovery and design, subsequently synthesis (including protection, coupling, and purification), and finally, structural modification and activity evaluation.

Key Players: Aragen Life Sciences, Bachem, GenScript Biotech Corporation, etc.

Clinical Trials and Regulatory Approval

After the successful phases of clinical trials

Key Players: Cardiff University, Instituto de Medicina Regenerativa, Egymedicalpedia, etc.

Patient Support & Services

Companies are facilitating different financial assistance, programs, and educational programs, whereas healthcare providers are supporting weight management in diabetic patients

Key Players: Eli Lilly, Novartis, Merck & Co., etc.

Key Companies and Their contributions and offerings

• Novo Nordisk A/S- In September 2025, Novo Nordisk presented a paper introducing PepFuNN, an open-source Python package for in-silico analysis of peptides.
• Eli Lilly and Company- In October 2025, it announced positive Phase 3 results for its oral peptide, orforglipron.
• Sanofi S.A.- In July 2025, it fostered 82 clinical-stage projects, with wider emphasis on immunology and neurology, areas where peptide therapies are highly relevant.
• Pfizer Inc – In September 2025, it was focused on the cardiometabolic space, especially through its acquisition of Metsera.
• Novartis International AG- In May 2024, it accelerated its peptide discovery collaboration with Japanese biotech company PeptiDream.
  

Browse More Insights of Towards Healthcare:

The gene synthesis market

The global DNA synthesis market

The gene synthesis service market

The global oligonucleotide synthesis market

The global healthcare data synthesis tools market

The global nanoparticle synthesis system market

The global peptide synthesis market

The global biosynthesis peptide drugs market

The global digital breast tomosynthesis market

The peptide-based weight loss medication market

Key Developments in the Chemical Synthesis Peptide Drugs Market

• In December 2025, Metropolis unveiled GLP-1 monitoring test packages to target the obesity market.
• In October 2025, Designs for Health launched Progenalen Pro Peptide, an advanced triple action solution for metabolic health and healthy ageing.
• In October 2025, ProImmune launched its ProVE SL Self-Loading MHC Class I Monomers, a new reagent platform developed to boost antigen-specific CD8+ T cell detection.
  

Chemical Synthesis Peptide Drugs Market Key Players Lists

• Takeda Pharmaceutical Company Limited
• AstraZeneca PLC
• Bristol-Myers Squibb (BMS)
• Merck & Co., Inc. (MSD)
• Amgen Inc.
• PolyPeptide Group
• Bachem AG
• Lonza Group Ltd.
• CordenPharma (part of Novacap/contract pharma group)
• AmbioPharm Inc.
• CPC Scientific / Chinese Peptide Company (CPC)
• ScinoPharm Taiwan Ltd.
• Peptide Institute, Inc.
• GenScript Biotech Corporation
• JPT Peptide Technologies GmbH.
  

Segments Covered in the Report

By Synthesis Method

• Chemical Synthesis
• Solid-Phase Peptide Synthesis (SPPS)
• Liquid-Phase Peptide Synthesis (LPPS)
• Hybrid Phase Synthesis
• Non-Chemical Synthesis
• Recombinant DNA Technology
• Group-Assisted Purification Peptide Synthesis (GAP-PS)
  

By Synthesis Technology

• Solid-Phase Peptide Synthesis (SPPS)
• Liquid-Phase Peptide Synthesis (LPPS)
• Hybrid Phase Peptide Synthesis
  

By Product Type

• Reagents & Consumables
• Amino Acids
• Coupling Reagents
• Equipment
• Peptide Synthesizers
• Automated Synthesizers
• Services
• Custom Peptide Synthesis
• Analytical Services
  

By End-User

• Pharmaceutical & Biotechnology Companies
• Pharmaceutical Companies
• Biotechnology Startups
• CDMOs/CROs
• Large CDMOs
• Mid-Sized CROs

By Application

• Therapeutics
  • Cancer Therapeutics
  • Diabetes Treatments
• Diagnostics
  • Infectious Disease Diagnostics
  • Cancer Biomarker Detection
• Research
  • Neuroscience Research
  • Immunology Studies
    

By Region

• North America
  • U.S.
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Thailand
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Norway
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • UAE
  • Saudi Arabia
  • Kuwait
    

Immediate Delivery Available | Buy This Premium Research @

Access our exclusive, data-rich dashboard dedicated to the healthcare market - built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.

Access the Dashboard:

About Us

Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research

You can place an order or ask any questions, please feel free to contact us at ...

Europe Region: +44 778 256 0738

North America Region: +1 8044 4193 44

APAC Region: +91 9356 9282 04

Web:

Our Trusted Data Partners

Precedence Research | Statifacts | Towards Packaging | Towards Automotive | Towards Food and Beverages | Towards Chemical and Materials | Towards Consumer Goods | Towards Dental | Towards EV Solutions | Nova One Advisor | Healthcare Webwire | Packaging Webwire | Automotive Webwire | Nutraceuticals Func Foods | Onco Quant | Sustainability Quant | Specialty Chemicals Analytics

Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | Pinterest